Adenocarcinoma of the Appendix: Understanding Your Pathology Report

Section Editor: David Driman MBChB FRCPC
November 17, 2026


Print this article

Adenocarcinoma of the appendix is a cancer that starts from the gland-forming cells lining the inside of the appendix. The appendix is a small pouch attached to the first part of the large bowel. This type of cancer forms glands that look much like those of colon cancer, so it is also called colonic-type, intestinal-type, or non-mucinous adenocarcinoma. Your pathology report will usually say “adenocarcinoma.”

This article explains how adenocarcinoma of the appendix differs from other appendix cancers and how it is graded and staged. It also explains what the margins, lymph nodes, and other findings in your pathology report mean.

How is adenocarcinoma different from other cancers of the appendix?

Several different cancers can start in the appendix, and each one is described differently in a pathology report. When a report says only “adenocarcinoma,” it means a gland-forming cancer that does not fit one of the more specific types below.

Adenocarcinoma accounts for about one in four cancers of the appendix. It behaves more like colon cancer than the other types, and it is less likely than mucinous adenocarcinoma to have spread inside the abdomen when it is found.

Who gets adenocarcinoma of the appendix?

Adenocarcinoma of the appendix is uncommon. Most people are diagnosed in their 50s or 60s. Like other appendix cancers, it has become more common over the past few decades, including in people under 50.

What causes adenocarcinoma of the appendix?

The cause of adenocarcinoma of the appendix is not known in most people. It is thought to develop in the same way as most colon cancers. First, a noncancerous growth called an adenoma or a serrated lesion forms in the appendix lining. Over time, the cells in that growth can acquire more genetic changes and become cancer.

The genes most often changed include KRAS and TP53. KRAS signals cells to keep dividing, while TP53 normally stops damaged cells from dividing. Rarely, the cancer is linked to an inherited condition called Lynch syndrome. This is described in the biomarker section below.

What are the symptoms of adenocarcinoma of the appendix?

Adenocarcinoma of the appendix often causes the same symptoms as acute appendicitis, such as pain in the lower right abdomen, fever, and nausea. The tumor causes these symptoms by blocking the appendix. Many cancers are therefore found unexpectedly after the appendix has been removed.

Other people notice a mass in the lower right abdomen, a change in bowel habits, or weight loss. When the cancer has spread, symptoms may include swelling of the abdomen or pain under the right ribs. Some cancers are found during a colonoscopy or a scan done for another reason.

How is the diagnosis made?

The diagnosis of adenocarcinoma of the appendix is usually made after the appendix is removed in a surgery called an appendectomy. Sometimes it is made on a biopsy taken during a colonoscopy, or after a larger operation called a right hemicolectomy. A pathologist examines the tissue under the microscope.

Under the microscope, the cancer cells form irregular glands that invade the appendix wall. The pathologist often finds an adenoma or serrated lesion in the lining next to the cancer. This finding helps confirm that the cancer started in the appendix.

A tumor at the base of the appendix may have started in the appendix or in the cecum, the first part of the large bowel. The pathologist must decide which. Cancers starting in the cecum are staged and reported as colon cancer. Stains such as CK20 and CDX2 confirm that the cancer is of bowel origin but cannot separate the appendix from the colon.

Once the diagnosis is made, a CT scan of the chest, abdomen, and pelvis is used to look for spread. A colonoscopy is also usually performed to check the rest of the large bowel. Blood tests for tumor markers, such as CEA, are often ordered.

Histologic grade

The grade of adenocarcinoma of the appendix describes how much the cancer cells still form glands. Tumors that form more glands look more like normal tissue. Grade helps predict how the cancer will behave and guides treatment decisions.

The College of American Pathologists (CAP) appendix protocol, version 5.1.0.0 (2022), uses three grades:

  • Well differentiated (G1). More than 95% of the tumor forms glands. These are well-differentiated tumors that tend to grow more slowly.
  • Moderately differentiated (G2). Between 50% and 95% of the tumor forms glands. Most adenocarcinomas of the appendix are moderately differentiated.
  • Poorly differentiated (G3). Less than 50% of the tumor forms glands. A poorly differentiated adenocarcinoma is more likely to spread to lymph nodes and distant organs.

Tumor extension

Adenocarcinoma of the appendix starts in the inner lining and grows outward through the wall. It can reach the submucosa, muscularis propria, and subserosa, and is covered on the outside by the serosa. The report also says whether the cancer has reached the mesoappendix, which is the fatty tissue holding the appendix and its blood vessels.

The deepest layer the cancer reaches determines the tumor stage (pT). Cancer that breaks through the serosa can spread to the lining of the abdomen, called the peritoneum.

Perineural invasion

Perineural invasion means adenocarcinoma cells were found growing along or around a nerve in or near the appendix. Cancer that follows nerves can reach tissue beyond the main tumor. Your report will state whether perineural invasion was “not identified,” “present,” or “cannot be determined” for the tissue examined.

Lymphovascular invasion

Lymphovascular invasion means adenocarcinoma cells were found inside a small blood vessel or lymphatic channel. Cancer cells in these channels can reach the lymph nodes, liver, or other organs. The report will state whether it was “not identified,” “present,” or “cannot be determined” for the tissue examined. Lymphovascular invasion is one of the features used to decide whether a right hemicolectomy is needed after an appendectomy.

Surgical margins

A margin is an edge of tissue cut by the surgeon to remove the adenocarcinoma. In an appendectomy, the proximal margin is where the appendix was divided from the large bowel. The mesenteric margin is the cut edge of the mesoappendix. In a right hemicolectomy, the cut ends of the small and large bowel are also examined.

Following the CAP appendix protocol, version 5.1.0.0 (2022), margins are reported as negative or positive, with no “close” category:

  • Negative margin. Every cut edge is free of cancer cells. Some reports add how far the cancer is from the mesenteric margin.
  • Positive margin. Cancer cells are present at a cut edge, and the involved margin is named. A positive margin after an appendectomy is a strong reason to consider a right hemicolectomy.

Lymph nodes

Lymph nodes are small immune organs that filter fluid draining from tissues. Adenocarcinoma of the appendix spreads to lymph nodes more often than most other appendix cancers. In a large United States study, about 1 in 4 people with this cancer had lymph node spread.

An appendectomy removes few or no lymph nodes, so a right hemicolectomy is usually needed to examine them. Surgeons usually examine at least 12 lymph nodes. The report gives the number examined and the number containing cancer. Some reports describe tumor deposits, meaning separate cancer nodules in the surrounding fat without lymph node tissue. It may also note extranodal extension, meaning cancer has grown through the outer capsule of a lymph node.

Tumors that are confined to the submucosa (pT1), well or moderately differentiated, and without lymphovascular invasion rarely spread to lymph nodes. In the same study, fewer than 2 in 100 of these low-risk tumors spread to lymph nodes.

Biomarker and molecular testing

Biomarker testing for adenocarcinoma of the appendix is similar to testing for colon cancer. It is most often performed when the cancer has spread or returned, to look for features that may open specific treatment options.

Mismatch repair (MMR) and microsatellite instability (MSI)

Mismatch repair proteins fix errors that occur when a cell copies its DNA. Testing looks at four proteins: MLH1, PMS2, MSH2, and MSH6. Testing uses immunohistochemistry for the proteins or a DNA test for microsatellite instability. Fewer than 2 in 100 appendix cancers are mismatch repair deficient.

  • Intact, retained, or proficient (pMMR), or microsatellite stable (MSS). All four proteins are present. This is the most common result.
  • Loss of expression, deficient (dMMR), or MSI-high. One or more proteins are missing. Pembrolizumab is approved by the FDA (2017) and Health Canada for unresectable or metastatic solid tumors with this result that have grown after earlier treatment. This result also leads to genetic counseling to test for Lynch syndrome.

KRAS, NRAS, and BRAF

KRAS, NRAS, and BRAF are genes that control cell growth signals. They are usually tested together by DNA sequencing, often as part of a larger next-generation sequencing panel.

  • No mutation in KRAS, NRAS, or BRAF (wild type). None of these genes is changed. Your oncologist will consider this result when choosing drug treatment, as is done for colon cancer.
  • KRAS or NRAS mutation. One of these genes is changed. KRAS mutations are found in more than half of appendix adenocarcinomas. Your oncologist will use this result to choose which drugs are likely to help.
  • BRAF V600E mutation. This specific BRAF change is present. Dabrafenib with trametinib received accelerated approval from the FDA in 2022 for solid tumors with this change that have grown after earlier treatment.

Tumor mutational burden (TMB)

Tumor mutational burden is the number of gene changes in the cancer, measured in mutations per megabase (mut/Mb) by next-generation sequencing.

  • TMB-low. Fewer than 10 mut/Mb. This is the most common result.
  • TMB-high. 10 or more mut/Mb. Pembrolizumab received accelerated approval from the FDA in 2020 for TMB-high solid tumors that have grown after earlier treatment.

The Biomarkers and Genetic Testing section explains these tests in more detail, including our articles on KRAS, NRAS, and BRAF in colorectal cancer.

Pathologic stage (pTNM)

The American Joint Committee on Cancer (AJCC) system for appendix carcinomas, Version 9 (2023), is used to stage adenocarcinoma of the appendix. The pathologist assigns the tumor stage (pT) and nodal stage (pN), and imaging usually assesses distant spread. See our article on TNM staging to learn how the stage groups are formed.

Tumor stage (pT)

  • pTis. Cancer cells are present only in the lining and have not reached the submucosa.
  • pT1. The cancer has grown into the submucosa.
  • pT2. The cancer has grown into the muscularis propria.
  • pT3. The cancer has grown through the muscle into the subserosa or mesoappendix.
  • pT4a. The cancer has grown through the serosa.
  • pT4b. The cancer has grown directly into a nearby organ or structure.
  • pTX. The tumor cannot be assessed.

Nodal stage (pN)

  • pN0. No cancer is present in the lymph nodes examined.
  • pN1a. Cancer is present in one lymph node.
  • pN1b. Two or three lymph nodes contain cancer.
  • pN1c. Tumor deposits are present, but the lymph nodes are free of cancer.
  • pN2. Four or more lymph nodes contain cancer.
  • pNX. No lymph nodes were examined, as is common after an appendectomy alone.

Distant spread to the lining of the abdomen is M1b, and spread beyond it, such as to the liver or lungs, is M1c. For M1b disease, a grade 1 cancer is stage IVA, while a grade 2 or grade 3 cancer is stage IVB.

What is the prognosis?

The prognosis for adenocarcinoma of the appendix depends mainly on the stage. In a Japanese multicenter study, about 91% of people with stage 0 or I disease were alive after 5 years. The figure was about 69% for stage II or III and about 7% for stage IV. In other words, about 93% of people with stage IV disease were not alive at 5 years. In a United States referral-center series, 3-year survival was 87% for stage I to II, 55% for stage III, and 36% for stage IV.

Once the cancer has spread to distant sites, adenocarcinoma of the appendix generally has a less favorable outlook than mucinous adenocarcinoma. The findings linked to a worse outlook are:

  • Distant spread. Spread to the lining of the abdomen, liver, or lungs is the strongest predictor of a poor outcome.
  • Lymph node spread. More involved lymph nodes mean a higher stage and a higher risk of recurrence.
  • Poorly differentiated (G3) tumor. High-grade tumors are more likely to spread.
  • Growth through the serosa (pT4). Tumor on the outer surface can seed the abdominal cavity.
  • Lymphovascular invasion. Cancer cells in vessels raise the risk of spread to lymph nodes and other organs.
  • Positive margin. Cancer at a cut edge raises the risk of the cancer returning.

What happens after the diagnosis?

After adenocarcinoma of the appendix is confirmed, the next steps depend on the stage, grade, margins, and lymph node results. Treatment is usually similar to that for colon cancer. A team that includes a surgeon and a medical oncologist plans care. The NCCN released a dedicated appendix cancer guideline for the first time in 2025.

  • Right hemicolectomy. When the cancer is found after an appendectomy, a right hemicolectomy is usually recommended to remove the lymph nodes and any remaining tumor. In a large study, people who did not have this operation had worse survival overall. The difference was not seen for small, low-risk tumors, so your surgeon will consider your report’s findings.
  • Chemotherapy after surgery. Chemotherapy is usually recommended when the lymph nodes contain cancer, as for colon cancer. In a large United States database study, chemotherapy after surgery was linked to longer survival for stage I to III disease.
  • Cancer that has spread. Chemotherapy similar to that used for colon cancer is the main treatment. Biomarker results help choose the drugs. When spread is limited to the lining of the abdomen, cytoreductive surgery with heated chemotherapy (HIPEC) may be considered at a specialist center.
  • Follow-up. Regular visits, CT scans, CEA blood tests, and colonoscopy are used to watch for the cancer returning.

If testing suggests Lynch syndrome, genetic counseling can help you and your family members understand their risk.

Questions to ask your doctor

  • Is my cancer an adenocarcinoma of the appendix, or did it start in the cecum?
  • Was an adenoma or serrated lesion found next to the cancer?
  • What is the grade of my tumor?
  • How deeply did the cancer grow, and did it reach the serosa or the mesoappendix?
  • Were the proximal and mesenteric margins negative?
  • Was lymphovascular or perineural invasion found?
  • Do I need a right hemicolectomy, and why?
  • How many lymph nodes were removed, and how many contained cancer?
  • What is my stage?
  • Was mismatch repair testing done, and do I need genetic counseling?
  • Were KRAS, NRAS, BRAF, or other biomarker tests done, and what did they show?
  • Is chemotherapy recommended for me, and why?
  • Do I need a colonoscopy, and how often should I have one in the future?
  • How will I be followed after treatment?

Related articles on MyPathologyReport.com

A+ A A-
Was this article helpful?